Polycystic Ovary Syndrome Renamed to Better Reflect Its Broader Metabolic Impact in 170 Million Women

On May 12, 2026, a paper published in The Lancet formally retired one of medicine's most criticized labels. Polycystic ovary syndrome — PCOS — became polyendocrine metabolic ovarian syndrome, or PMOS [1]. The change, presented the same day at the European Congress of Endocrinology in Prague, was the product of a 14-year global consensus process involving more than 22,000 patients, clinicians, and researchers across 56 organizations [2]. It was approved by 87 of 90 voting members of the Global Name Change Consortium [3].

The old name, coined decades ago, described a condition by one of its least defining features: the appearance of small follicles on the ovaries, which are neither cysts nor present in all patients. The new name is meant to signal what the condition actually is — a multisystem endocrine and metabolic disorder with reproductive, dermatological, and psychological dimensions [1]. Whether this lexical correction translates into better care for 170 million affected women is the question that now hangs over global health systems.

A Name That Misled for Decades

The problems with "polycystic ovary syndrome" have been documented since at least 1995 [4]. The name implies pathological ovarian cysts, but the "cysts" visible on ultrasound are actually immature follicles — a normal variation in many women. Not all patients with the condition have them, and not all women with polycystic-appearing ovaries have the syndrome [5]. As a 2012 NIH Evidence-based Methodology Workshop concluded, "the name focuses on a criterion — polycystic ovarian morphology — which is neither necessary nor sufficient to diagnose the syndrome" [4].

That NIH panel recommended a name change. Nothing happened. A 2015 meeting in Sicily brought together leading experts, but they could not agree on a replacement [3]. Several subsequent proposals stalled for lack of coordinated international leadership, alignment between patient advocacy groups, and a clear implementation strategy [2].

The effort that ultimately succeeded was led by Helena Teede, an endocrinologist at Monash University in Australia, who assembled the global consortium and administered three rounds of surveys — in 2017, 2023, and 2025 — to nearly 15,000 stakeholders in the final round alone [3]. Key figures who had pushed for the change over years, including Ricardo Azziz, Andrea Dunaif, Bart Fauser, and Robert Norman, participated in the process [4].

What the New Name Encodes

Each word in "polyendocrine metabolic ovarian syndrome" was chosen to signal specific pathophysiology. "Polyendocrine" reflects that the condition involves multiple hormonal systems — not just the ovaries — including androgen excess and hypothalamic-pituitary-adrenal (HPA) axis dysregulation [1]. "Metabolic" points to insulin resistance, which is present in an estimated 50–80% of patients across phenotypes and is increasingly understood as a central driver of the syndrome rather than a comorbidity [6]. "Ovarian" retains the reproductive dimension, acknowledging that ovulatory dysfunction and fertility impacts remain core features. "Syndrome" persists because the condition is diagnosed by a cluster of signs rather than a single biomarker [1].

The metabolic dimension is where the strongest case for renaming lies. Insulin resistance in PCOS operates through distinctive molecular mechanisms — selectively impairing the PI3K/Akt signaling pathway while leaving the MAPK pathway intact, a pattern distinct from other insulin-resistant states like type 2 diabetes [6]. Hyperinsulinemia drives ovarian theca cells to overproduce androgens, creating a self-reinforcing cycle: excess insulin increases androgen production, which in turn suppresses sex hormone-binding globulin, freeing more circulating androgens [7]. Approximately 43% of adult women with the condition meet criteria for metabolic syndrome [6].

Yet some of these mechanisms remain actively debated. The role of HPA-axis dysregulation, for instance, is supported by some studies but lacks consensus in the broader literature [7]. Critics argue that encoding contested science into a clinical name risks ossifying hypotheses that may need revision as research advances.

The Diagnostic Gap

The WHO estimates that up to 70% of women with the condition remain undiagnosed worldwide [8]. A UK retrospective cohort study of more than 2 million women found that only 1.34% of reproductive-age women had a recorded PCOS diagnosis, rising to 2.27% if probable cases were included — suggesting roughly half of diagnosable patients were missed [9].

Diagnostic delays are substantial: patients commonly see multiple physicians over several years before receiving a diagnosis. A longer path to diagnosis correlates with lower satisfaction with healthcare services and greater psychological distress [9].

These delays are not distributed equally. A study published in the Journal of Clinical Endocrinology & Metabolism found that Black patients had 1.69 times the odds of a missed diagnosis compared to white patients, while those on Medicaid or charity insurance had 1.90 times the odds of being missed compared to those with private insurance. Non-English speakers also faced elevated odds of missed diagnosis [10].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Research output on the condition has grown steeply — from 2,190 published papers in 2011 to a peak of 12,568 in 2025, totaling nearly 88,000 papers to date [11]. But whether the name itself, rather than physician training gaps, overlapping diagnostic criteria, or insurance-driven access barriers, is the primary cause of diagnostic failures remains an open empirical question. PCOS Challenge, one of the two organizations that voted against the rename, has called for documented evidence that renaming specifically improves diagnosis timelines before the transition proceeds [12].

A Global Burden Concentrated in Middle-Income Nations

The Global Burden of Disease Study 2021 counted 65.8 million prevalent cases worldwide — an 89% increase from 34.8 million in 1990 [13]. The highest absolute numbers are in South Asia, followed by East Asia and the Pacific.

Source: GBD 2021 via Frontiers in Public Health

Data as of Jan 1, 2025CSV

The condition's burden correlates positively with the Sociodemographic Index (SDI), a composite measure of income, education, and fertility. Middle-SDI regions carry the highest case numbers, with the 45–49 age group in these regions experiencing the most significant burden increase [13]. This complicates the narrative that a name change alone would close the diagnostic gap. In low-income countries, the barriers are structural: limited specialist access, weak primary care infrastructure, and absent screening protocols. In sub-Saharan Africa and parts of South Asia, informal healthcare providers often serve as the first point of contact — providers unlikely to diagnose a complex endocrine condition regardless of what it is called [14].

Obesity, a major risk multiplier for the metabolic features of the condition, varies dramatically by country. The United States leads high-income nations at 42%, while India and Japan sit below 8% [15]. These differences shape how the condition presents and how health systems encounter it.

Source: WHO Global Health Observatory

Data as of Dec 31, 2022CSV

Who Gains, Who Loses

Reclassifying the condition from primarily reproductive/gynecological to metabolic carries financial and institutional implications. Under the old framing, PCOS research and clinical care fell largely under gynecology departments and reproductive endocrinology. Funding agencies, medical education curricula, and journal editorial categories reflected this [1]. A metabolic framing could broaden research funding eligibility, open the condition to metabolic and endocrinology specialists, and potentially expand insurance coverage for metabolic screenings and treatments.

The Lancet paper notes explicit engagement with "governments, research funders, journal editors, regulators, and the health-care industry (including the pharmaceutical industry)" to support adoption [1]. The pharmaceutical angle is significant: drugs like metformin (an insulin sensitizer) and GLP-1 receptor agonists are already used off-label in PCOS management. A metabolic classification could strengthen the case for formal indication approvals, expanding the market for these therapies.

The consensus process was led by Monash University with funding and governance structures involving 56 organizations [2]. The specific funding sources for the consortium's work are not fully detailed in the published materials, making it difficult to assess whether pharmaceutical companies or insurers with a stake in reclassification contributed to the research supporting the rename.

The Case Against — and the Risks of Transition

Not everyone sees the rename as an advance. The National Polycystic Ovary Syndrome Association acknowledged the effort was done "in the spirit of what is right," but declined to endorse the change [12]. PCOS Challenge, one of the largest U.S. patient advocacy organizations, issued a detailed response identifying four claims it considers unproven: that the old name caused documented harms; that renaming is the corrective solution; that PMOS is the optimal replacement term; and that this process should model future medical renamings [12].

Sasha Ottey, executive director of PCOS Challenge, stated: "For many in the PCOS community, today is complicated. Some are concerned it will cause more harm than the problems it aims to fix. Some are exhausted by decades of misdiagnosis, dismissal, and unmet need" [12].

The organization drew a distinction between administrative uptake — updating classification systems and electronic health records — and actual clinical change. The real barriers to better care, they argued, include training gaps, referral patterns, reimbursement structures, research categorization, clinical jurisdiction, and health-system capacity [12]. A name change addresses none of these directly.

There is also the practical matter of transition infrastructure. The current ICD-10-CM code for the condition is E28.2, classified under "Ovarian dysfunction" [16]. Changing ICD codes requires action by the WHO's ICD revision committees and subsequent adoption by national health systems — a process that typically takes years. During any transition period, old and new names would coexist in medical records, creating potential for fragmentation in clinical data, insurance claims processing, and epidemiological surveillance.

Active clinical trials registered under "PCOS" — thousands are listed on ClinicalTrials.gov — would need updated terminology in their registries, publications, and regulatory submissions. Drug approvals currently referencing PCOS in their labeling would require regulatory review. The cost and timeline for these updates across global systems have not been publicly estimated.

Dr. Melanie Cree, a pediatric endocrinologist at the University of Colorado Anschutz Medical Campus and one of only two U.S.-based pediatric endocrinologists involved in the consortium, offered a counterpoint: "Renaming this condition is more than semantics; it's about finally recognizing the full reality of what patients experience. Language matters in medicine" [17].

What Actually Needs to Change

The two dissenting voters — Grassi and Ottey — raised a point that the rename's supporters have not fully addressed: the new name retains "ovarian," which may not accommodate emerging research on potential male presentations of the condition [3]. If PMOS is meant to be the definitive correction, its continued gendering of the syndrome could require yet another revision.

More fundamentally, whether the rename improves outcomes depends on what accompanies it. The Lancet paper outlines "coordinated implementation" across health systems, research institutions, funding bodies, education providers, clinical guidelines, and disease classification systems, supported by a global transition period and continuous evaluation [1]. That is an ambitious program. Whether it materializes — or whether the name change becomes an end in itself, celebrated as progress while the structural barriers to diagnosis and care persist — will determine whether PMOS becomes a genuinely different chapter in the condition's history or a relabeling of the same failures.

For the estimated 46 million women who have the condition but don't know it [8], the name on the diagnosis matters less than whether a diagnosis arrives at all.